Ascendis Pharma Officer Files Intent to Sell $45.7K in Stock
Ascendis Pharma A/S
Subscribe to track ASND
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Ascendis Pharma Officer Files Intent to Sell $45.7K in Stock
Company: Ascendis Pharma A/S (ASND) Form: 144 | Filed: 2025-12-01 Significance: Low
Insider: SINGEL STINA Title: Not Specified | Relationship: Officer
Transaction (Proposed Sale): • Type: Sale • Shares: 218 • Value: $45,679.72 • Price: ~$209.54/share
Key Insight: An officer has filed a notice of a proposed sale of a very small number of shares, representing a negligible fraction of the company's market capitalization. This is a routine filing with minimal market significance.
Market Context: The transaction value is less than 0.001% of the company's $12.49 billion market cap. The shares are noted as being acquired via warrant exercise on the same day, suggesting a potential sale to cover exercise costs or taxes.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Ascendis Pharma A/S (ASND)
Executive Summary
- Trading Significance: Low
- Key Takeaway: An officer filed a notice of a proposed sale of shares valued at approximately $45.7K, a negligible amount for a company of this size.
- Market Impact: The transaction is too small to have any meaningful impact on the stock.
Company Information
| Field | Value |
|---|---|
| Company | Ascendis Pharma A/S |
| Ticker Symbol | ASND |
| CIK | 0001612042 |
| Industry | PHARMACEUTICAL PREPARATIONS |
Insider Information
| Field | Value |
|---|---|
| Name | SINGEL STINA |
| CIK | 0001965496 |
| Title/Position | Not Specified |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 |
| Transaction Date | 2025-12-01 (Approximate Sale Date) |
| Transaction Code | S (Proposed Sale) |
| Security Type | American Depositary Shares |
| Shares Involved | 218 |
| Price Per Share | ~$209.54 |
| Total Value | $45,679.72 |
| Shares Owned After | Not Specified |
| Ownership Type | Not Specified |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $45,679.72 |
| % of Market Cap | <0.001% |
| Shares Transacted | 218 |
| % of Shares Outstanding | <0.001% |
| Post-Transaction Ownership | Not Specified |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The proposed sale of $45.7K is insignificant against Ascendis Pharma's market capitalization of $12.49 billion.
- Transaction Significance: The transaction represents a minuscule fraction of both the market cap and the total shares outstanding (61,695,211), indicating it is not a strategic move by the insider but likely a routine financial management activity.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The size of the proposed sale is immaterial and will not influence market perception or trading activity.
Volume & Sentiment
- Expected Volume Impact: None. The transaction is too small to be noticeable in daily trading volume.
- Sentiment Indicator: Neutral. This filing does not provide any signal regarding the insider's confidence in the company's future prospects.
Additional Context
Transaction Notes
- This Form 144 is a notice of a proposed sale, not a completed transaction.
- The filing indicates the shares were acquired via a warrant exercise on the same day as the proposed sale date. This often occurs when insiders sell shares to cover the cost of the exercise and associated taxes.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.